Govt to pharma firms: Ramp up Remdesivir Mfg to full capacity

The direction comes against reports of shortages of the critical drug.

355

Last Updated on April 10, 2021 by The Health Master

The government said that all seven manufacturers of remdesivir in the country have been asked to ramp up production to full capacity by next week.

The direction comes against reports of shortages of the critical drug.

Remdesivir is considered as a key antiviral drug in the fight against C-19, especially in adult patients with severe complications.


Read more about Remdesivir, click here


“There are seven players who produce remdesivir. I have asked all players to ramp up production to full capacity by next week. The drug’s API is manufactured in India so there won’t be a problem,” Mansukh Mandaviya, Minister of State for Chemical and Fertilizers, told PTI.

Medicine Injection Vaccine
Picture: Pixabay

Mandaviya said these seven manufacturers – Mylan, Hetero, Jubiliant Life Sciences, Cipla, Dr Reddy’s, Zydus Cadila and Sun Pharma – have a monthly production capacity of 31.60 lakh vials.

Letters have been despatched to all these drugmakers to ramp up production, he added.

Of the 31.60 lakh vials, Hetero produces 10.50 lakh vials a month, Cipla makes 6.20 lakh vials, 5 lakh vials are produced by Zydus Cadila and 4 lakh vials are produced by Mylan, Mandaviya said.

The remaining drugmakers produce vials in the range of 1 lakh and 2.5 lakh a month, he added.


Also read:

NABH extended validity of accreditation for Hospitals

Shortage of containers hits exports of pharmaceuticals from India

Complaint boxes to fight drug menace: AP

Crystec Pharma launches new R&D centre in Haimen, China

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner